Related Experiment Videos
Hypogonadal impotence treated by transdermal testosterone.
R D McClure1, R Oses, M L Ernest
1Department of Urology, University of California, School of Medicine, San Francisco.
Urology
|March 1, 1991
Summary
The transdermal therapeutic system for testosterone (TTS-T) improved hypogonadal impotence by restoring testosterone and dihydrotestosterone (DHT) levels. This convenient treatment enhanced erectile function, mood, and energy without significant side effects.
Area of Science:
- Endocrinology
- Urology
- Dermatology
Background:
- Hypogonadal impotence affects men's erectile function, mood, and energy.
- Conventional testosterone replacement methods have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of a transdermal therapeutic system for testosterone (TTS-T) in men with hypogonadal impotence.
- To assess the impact of TTS-T on hormonal levels, erectile function, and overall well-being.
Main Methods:
- A 12-week study involving 4 hypogonadal men using TTS-T applied to scrotal skin.
- Two system sizes (40 cm2 and 60 cm2) delivered daily doses of testosterone.
- Serum testosterone, dihydrotestosterone (DHT), and other relevant markers were monitored.
Main Results:
- TTS-T promptly normalized serum testosterone and DHT levels.
- Restored erectile activity, increased ejaculation frequency, and improved mood and energy were observed.
- No significant adverse effects on prostate, breast, hematologic, liver function, or urinary measures were noted. A slight decline in HDL was observed.
Conclusions:
- TTS-T effectively treats hypogonadal impotence by mimicking natural testosterone secretion.
- The scrotal skin's 5-alpha reduction of testosterone significantly increased DHT levels.
- TTS-T offers a convenient and reliable alternative for testosterone replacement therapy.